Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018

References

• Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18(16):1871–1874.
   PubMed Web of Science ®Google Scholar
• Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma. 2009;50(7):1083–1095.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Drug Insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3(2):86–95.
   PubMedGoogle Scholar
• Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62(Suppl 2):ii55–ii59.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–2081.
   PubMed Web of Science ®Google Scholar
• Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018;5(2):118.
   PubMed Web of Science ®Google Scholar
• Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(1 Suppl 2):3–8.
   PubMed Web of Science ®Google Scholar
• Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13(11):1365–1368.
   PubMed Web of Science ®Google Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56(8):2715–2718.
   PubMed Web of Science ®Google Scholar
• Blombery P, Prince HM, Levinson M, et al. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol. 2011;29(5):e110–e112.
   PubMed Web of Science ®Google Scholar
• Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126(1):e243–e246.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008;57(5):714–715.
   PubMed Web of Science ®Google Scholar
• Bhalme M, Hayes S, Norton A, et al. Rituximab-associated colitis. Inflamm Bowel Dis. 2013;19:E41.
   PubMed Web of Science ®Google Scholar
• Lipka S, Katz S, Crawford JM. Fulminant colitis following rituximab therapy. Gastroenterol Hepatol. 2016;12:58–60.
   PubMedGoogle Scholar
• Fraser D, Boyle S, Amft N. Perianal Crohn disease after treatment with rituximab for active granulomatosis with polyangiitis. J Rheumatol. 2016;43(12):2199–2200.
   PubMed Web of Science ®Google Scholar
• Varma P, Falconer J, Aga A, et al. Rituximab-induced Crohn's disease. Scand J Gastroenterol. 2017;52(5):606–608.
   PubMed Web of Science ®Google Scholar
• Mizoguchi E, Mizoguchi A, Preffer FI, et al. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000;12(5):597–605.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Smith RN, et al. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med. 1997;186(10):1749–1756.
   PubMed Web of Science ®Google Scholar
• Björnsson S, Tryggvason FP, Jónasson JG, et al. Incidence of inflammatory bowel disease in Iceland 1995 - 2009. A nationwide population-based study. Scand J Gastroenterol. 2015;50(11):1368–1375.
   PubMed Web of Science ®Google Scholar
• Tang DM, Urrunaga NH, De Groot H, et al. Pseudomembranous colitis: not always caused by Clostridium difficile. Case Rep Med. 2014;2014:812704.
   PubMedGoogle Scholar
• Dubeau M-F, Iacucci M, Beck PL, et al. Drug-induced inflammatory bowel disease and IBD-Like conditions. Inflamm Bowel Dis. 2013;19:445–456.
   PubMed Web of Science ®Google Scholar
• Ahluwalia B, Magnusson MK, Öhman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 2017;52(11):1185–1193.
   PubMed Web of Science ®Google Scholar
• Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–99.
   PubMed Web of Science ®Google Scholar
• Tedder TF. B10 cells: a functionally defined regulatory B cell subset. J Immunol. 2015;194(4):1395–1401.
   PubMed Web of Science ®Google Scholar
• Davidson NJ, Leach MW, Fort MM, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 1996;184(1):241–251.
   PubMed Web of Science ®Google Scholar
• Jamin C, Morva A, Lemoine S, et al. Regulatory B lymphocytes in humans: a potential role in autoimmunity. Arthritis Rheum. 2008;58(7):1900–1906.
   PubMed Web of Science ®Google Scholar
• Mauri C, Gray D, Mushtaq N, et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003;197(4):489–501.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010;184(9):4801–4809.
   PubMed Web of Science ®Google Scholar
• Amu S, Saunders SP, Kronenberg M, et al. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010;125(5):1114–1124.e8.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317.
   PubMed Web of Science ®Google Scholar
• Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself. 2010;1(4):299–309.
   PubMedGoogle Scholar
• Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62(12):1795–1805.
   PubMed Web of Science ®Google Scholar
• Bae JM, Choo JY, Kim K-J, et al. Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: a nationwide population-based study. Mod Rheumatol. 2017;27(3):435–440.
   PubMed Web of Science ®Google Scholar
• Robinson D, Hackett M, Wong J, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006;22(5):989–1000.
   PubMed Web of Science ®Google Scholar